Revenue fell from $2.2M in 2024Q3 to $1.2M in 2026Q3 while R&D rose to $45.6M and the operating margin reached -48.3% in 2026Q3 (-244.9% in 2025Q4), indicating costs are scaling far faster than any recurring revenue base.
Dianthus Therapeutics, Inc. (DNTH) annual income statement — 10-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 2.72M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -11.7% | -67.35% | 120.63% | -55.96% | 334.76% | - | - | - | - | - | - |
| Cost of Goods Sold | 76K | 0 | 0 | 0 | 0 | 0 | 1.98M | 1.84M | 875K | 376K | 6K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 2.64M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | -1.98M | -1.84M | -875K | -376K | -6K |
| Gross Margin % | 97.2% | 100% | 100% | 100% | 100% | 100% | - | - | - | - | - |
| Gross Profit Growth % | - | -67.35% | 120.63% | -55.96% | 334.76% | 174.62% | -7.32% | -110.63% | -132.71% | -6166.67% | - |
| Operating Expenses | 238.67M | 179.97M | 108.1M | 51M | 36.12M | 14.56M | 76.72M | 81.13M | 59.09M | 35.35M | 9.26M |
| OpEx % of Revenue | - | 8839.34% | 1733.75% | 1804.67% | 562.91% | 986.59% | - | - | - | - | - |
| Selling, General & Admin | 50.04M | 34.33M | 24.99M | 18.16M | 6.74M | 1.96M | 28.09M | 23.76M | 17.75M | 7.45M | 3.48M |
| SG&A % of Revenue | - | 1686.2% | 400.87% | 642.57% | 105.08% | 132.52% | - | - | - | - | - |
| Research & Development | 188.71M | 145.64M | 83.11M | 32.84M | 29.38M | 12.61M | 48.64M | 57.37M | 41.34M | 27.9M | 5.78M |
| R&D % of Revenue | - | 7153.14% | 1332.88% | 1162.1% | 457.83% | 854.06% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -236.03M | -177.93M | -101.86M | -48.17M | -29.7M | -13.09M | -78.7M | -82.97M | -59.96M | -35.73M | -9.27M |
| Operating Margin % | -8683.89% | -8739.34% | -1633.75% | -1704.67% | -462.91% | -886.59% | - | - | - | - | - |
| Operating Income Growth % | - | -74.68% | -111.45% | -62.17% | -127% | 83.37% | 5.14% | -38.37% | -67.84% | -285.49% | - |
| EBITDA | -235.64M | -177.5M | -101.45M | -47.82M | -29.56M | -11.07M | -76.72M | -81.13M | -59.09M | -35.35M | -9.26M |
| EBITDA Margin % | -8669.57% | -8718.32% | -1627.14% | -1692.11% | -460.62% | -749.73% | - | - | - | - | - |
| EBITDA Growth % | -68.44% | -74.96% | -112.16% | -61.78% | -167.11% | 85.58% | 5.43% | -37.3% | -67.15% | -281.68% | - |
| D&A (Non-Cash Add-back) | 389K | 428K | 412K | 355K | 147K | 2.02M | 1.98M | 1.84M | 875K | 376K | 6K |
| EBIT | -39.79M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M | -74.94M | -76.77M | -57.52M | -35.49M | -9.27M |
| Net Interest Income | 35.22M | 16.12M | 17.36M | 4.76M | 1.15M | 100K | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 35.22M | 16.12M | 17.36M | 4.76M | 1.15M | 100K | 3.77M | 0 | 2.45M | 236K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 3.77M | 0 | 0 | 0 | 163K |
| Other Income/Expense | 196.24M | 15.6M | 16.89M | 4.62M | 1.23M | -23K | 3.77M | 6.2M | 2.45M | 236K | -163K |
| Pretax Income | -39.79M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M | -74.94M | -76.77M | -57.52M | -35.49M | -9.43M |
| Pretax Margin % | -1463.83% | -7973.33% | -1362.77% | -1541.22% | -443.76% | -888.14% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 236K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.66% | 0% |
| Net Income | -39.79M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M | -74.94M | -76.77M | -57.52M | -35.49M | -9.43M |
| Net Margin % | -1463.83% | -7973.33% | -1362.77% | -1541.22% | -443.76% | -888.14% | - | - | - | - | - |
| Net Income Growth % | 68.51% | -91.05% | -95.08% | -52.95% | -117.22% | 82.51% | 2.39% | -33.48% | -62.06% | -276.32% | - |
| Net Income (Continuing) | -39.79M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M | -74.94M | -76.77M | -57.52M | -35.49M | -9.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.69 | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 | -33.18 | -27.62 | -16.05 | -4.27 |
| EPS Growth % | 100.86% | -64.71% | 69.82% | -11.18% | -98.95% | 86.01% | 17.72% | -20.13% | -72.09% | -275.88% | - |
| EPS (Basic) | - | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 | -33.18 | -27.62 | -16.05 | -4.27 |
| Diluted Shares Outstanding | 57.34M | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M | 2.75M | 2.31M | 2.08M | 2.21M | 2.21M |
| Basic Shares Outstanding | 57.34M | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M | 2.75M | 2.31M | 2.08M | 2.21M | 2.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying DNTH stock.
For fiscal year 2025, Dianthus Therapeutics, Inc. (DNTH) reported total revenue of $2.0M.
Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $162.3M for the fiscal year ending 2025.
Dianthus Therapeutics, Inc. (DNTH) reported an operating income of $-177.9M, resulting in an operating profit margin of -8739.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Dianthus Therapeutics, Inc. (DNTH) generated $2.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Clinical-stage cash burn and dilution
Metrics are mathematically derived from official filings.
Legacy Revenue Wind-Down Continues
Based on reported quarterly figures, DNTH's revenue fell from $2.2M in 2024Q3 to $1.2M in 2026Q3 with year-over-year growth swinging between sharp declines and volatile rebounds, suggesting legacy collaboration income is not recurring.
The revenue series is lumpy and dominated by milestone-type receipts rather than any product or royalty base, so quarterly growth rates carry little information about underlying commercial momentum. The reported 2.1% year-over-year gain in 2026Q3 appears to reflect timing of a single receipt rather than a durable trend. Investors should treat the revenue line as incidental to the investment case and monitor whether it stabilizes or simply reverts to zero.
Operating Losses Scale With R&D Spend
As reported in the income statement, DNTH's R&D expense rose from $18.1M in 2024Q2 to $45.6M in 2026Q3, pushing operating losses to -$58.5M, which indicates operating costs are scaling far faster than any revenue base.
Because revenue is negligible, operating leverage works in reverse: each incremental dollar of clinical spending deepens the operating deficit rather than improving margins. SG&A has grown more modestly, from $6.0M to $14.1M, which suggests the cost base is dominated by program execution rather than overhead. The trajectory implies that any path to breakeven is entirely dependent on future commercial revenue that is not yet visible in the data.
Net Income Distorted by Non-Operating Items
Based on EDBL-style reporting logic applied here, DNTH's 2025Q4 net income of $97.9M against an operating loss of -$69.5M suggests a large non-operating gain that is unrelated to core clinical activity.
The swing from a deep operating loss to positive net income in 2025Q4 appears driven by items below the operating line, such as warrant revaluation, other income, or merger-related accounting, rather than improved operations. Stock-based compensation of $6.0M to $12.7M over the period is also material relative to revenue and merits attention as a non-cash cost. Analysts should strip these items out when assessing the true economic loss per share.
Cash Burn Outpaces Visible Funding
Based on reported figures, DNTH's quarterly operating loss near -$58.5M in 2026Q3 against a reported $51M cash balance suggests the runway may be under one year if burn persists at current levels.
This is an analytical inference from reported figures rather than disclosed guidance, since the latest report provided no runway commentary. The gap between quarterly burn and cash on hand raises the probability of a dilutive financing or partnership event in the near term, which could pressure per-share economics. Investors should monitor financing announcements and any change in R&D trajectory as the key signals.
R&D Dominates a Rising Cost Base
As reported in the income statement, R&D expense of $45.6M in 2026Q3 represents roughly 77% of total operating expenses, indicating that clinical program spending drives nearly all of the cost base.
The expense mix is consistent with a clinical-stage developer running multiple concurrent trials, where enrollment and CRO activity set the cost trajectory. SG&A has been held at a comparatively stable share, which may reflect disciplined overhead management following the reverse merger. Any slowdown in trial execution would likely be visible first in R&D and should be watched as a leading indicator of pipeline timing.